| 郑勤红,胡 伟,廖小方.顺铂序贯恩度与单纯顺铂胸腔内灌注治疗恶性胸腔积液的临床对照研究[J].肿瘤学杂志,2013,19(5):386-389. |
| 顺铂序贯恩度与单纯顺铂胸腔内灌注治疗恶性胸腔积液的临床对照研究 |
| A Comparision Between Intrapleural Injection of Cisplatin Combined with Endostar and Cisplatin Alone in the Treatment for Malignant Pleural Effusion |
| 投稿时间：2012-12-11 |
| DOI：10.11735/j.issn.1671-170X.2013.05.B2012609 |
|
 |
| 中文关键词: 恩度 顺铂 恶性胸腔积液 |
| 英文关键词:endostar cisplatin pleural effusion, malignant |
| 基金项目:衢州市科技局（2011083） |
|
| 摘要点击次数: 1958 |
| 全文下载次数: 1165 |
| 中文摘要: |
| 摘 要：［目的］ 观察胸腔内灌注顺铂序贯恩度与单纯顺铂治疗恶性胸腔积液的疗效及安全性。［方法］ 120例患者随机分为单纯顺铂胸腔灌注组（对照组）和顺铂序贯恩度胸腔灌注组（试验组）。治疗前均先排尽胸水，对照组单纯注入顺铂 30~40mg，d1~3，治疗组在对照组基础上于第4d胸腔内滴注恩度90mg。比较两组疗效和不良反应。［结果］ 试验组患者CR 14例，PR 29例，SD 12例，PD 5例，总有效率为 71.67%；对照组患者CR 10 例，PR 21例，SD 20例，PD 9例，总有效率为 51.67%；两组总有效率差异具有统计学意义（χ2=5.08，P=0.02）。分层分析发现，恩度对大于1 000ml胸水患者效果较好，两组疗效差异有统计学意义。［结论］ 胸腔内灌注顺铂序贯恩度疗效优于单纯顺铂，特别对于胸水较多的患者，效果会更好，不增加化疗的不良反应，值得临床推广。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the efficacy and safety of intrapleural injection of cisplatin combined with endostar and cisplatin alone in the treatment for malignant pleural effusion. ［Methods］ One hundred and twenty patients were randomly divided into experimental group and control group. Before treatment the pleural effusions were drained. The experimental group was given cisplatin 30~40mg，d1~3 and endostar 90mg，d4. The control group was given the same treatment except for endostar. ［Results］ Among the 60 patients in the experimental group，14 cases were complete response(CR)，29 cases were partial response(PR)， 12 cases were stable disease (SD)，5 cases were progression of disease (PD)，the overall response rate was 71.67%；among the 60 patients in the control group，10 cases were CR，21 cases were PR，20 cases were SD，9 cases were PD，and the overall response rate was 51.67%. There was significant diffe-rence between the two groups(χ2=5.08，P=0.02). Stratified analysis showed that endostar (combined with cisplatin) had a significant efficacy to patients with hydrothorax over 1000ml. ［Conclusion］ The response on intrapleural injection of endostar combined with cisplatin is superior to that cisplatin alone in the treatment for malignant pleural effusion，especially for heavy hydrothorax and it does not increase chemotherapeutic toxicity. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|